source
- Former FDA cancer chief Pazdur says the agency should restructureRichard Pazdur, who spent more than two decades leading the FDA’s cancer drug reviews, said the agency has a “golden opportunity” to restructure after being struck last year by the Trump administra…Endpoints · 7d ago↗ source
- FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyoutGSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and th…Endpoints · 7d ago↗ source
- Arrowhead’s gene silencer competitive with Ionis’ in triglyceride diseaseArrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population. Data shared Wednesday showed that Arrowhead’s gene silencer R…